Post by Sam Gibbons

👩‍🔬💬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲: 𝟐𝟑𝐫𝐝 𝐉𝐮𝐧𝐞 𝟐𝟎𝟐𝟔 👨‍🔬💬 🦠 CARsgen Therapeutics announced the approval of satri‑cel, the first CAR‑T cell therapy globally for solid tumours, targeting Claudin18.2 in advanced gastric cancer. Clinical data showed meaningful response rates and durable efficacy in heavily pre‑treated patients, alongside a manageable safety profile. This milestone marks a significant breakthrough for CAR‑T beyond haematological cancers, validating its potential in solid tumours and opening the door for broader applications across oncology indications. 🧬 uniQure’s stock surged after the FDA reversed its earlier stance, clearing the path for a regulatory filing of its haemophilia B gene therapy, AMT‑061. The FDA accepted updated clinical data addressing prior concerns around durability and safety, signalling renewed regulatory confidence. The decision removes a major overhang for uniQure, strengthening its commercial outlook and reinforcing momentum following regulatory uncertainty. 🧬 VectorBuilder and MaxCyte, Inc. announced a strategic partnership to accelerate clinical‑grade cell engineering, combining VectorBuilder’s vector design and manufacturing expertise with MaxCyte’s scalable electroporation technology. The collaboration aims to streamline development of engineered cell therapies by offering an integrated workflow from gene delivery to clinical manufacturing. 🧬 Syntax Bio secured new funding, strengthened its leadership team and entered a strategic collaboration with Applied StemCell to accelerate development of programmable genetic medicines. This exciting string of events positions the company to scale R&D and advance next‑generation, precision gene therapies toward clinical application. 🧬 Houdini Bio raised $1.5M to advance its platform for targeted CGTs, designed to selectively eliminate diseased cells while sparing healthy tissue. The company’s approach aims to improve safety and precision across a range of genetic and oncology applications. The funding will support early development and validation, positioning Houdini Bio to contribute to next‑gen therapies that address key limitations in current CGT treatment modalities. 🧬 Legend Biotech has priced a $226M ADS offering to support expansion of its cell therapy pipeline and manufacturing capabilities. The raise strengthens the company’s financial position as it scales production and advances next‑generation CAR‑T programmes beyond its lead asset, Carvykti. The funding highlights continued investor confidence in commercial cell therapies and will help accelerate pipeline development and global capacity to meet growing demand. 🛎 My aim is to be the messenger when it comes to your CGT & RNA therapy news. Follow #mCGT to stay updated! #celltherapy #genetherapy #ATMP #advancedtherapy